Table 3 Patient characteristics stratified by CCI
|  | Low CCI (CCI < 21) (n = 45) | High CCI (CCI ≥ 21) (n = 8) | p |
|---|---|---|---|
Age | 70 (61–75) | 70 (68–76) | 0.742 |
Sex (male: female) | 32: 13 | 8: 0 | 0.087 |
BMI | 22.30 (20.50–24.68) | 22.15 (20.67–23.49) | 0.874 |
ASA (1: 2: 3) | 1: 40: 4 | 0: 8: 0 | 1.000 |
Hypertension (%) | 11/45 (24.4) | 4/8 (50.0) | 0.147 |
Hyperlipidemia (%) | 2/45 (4.5) | 1/8 (12.5) | 0.394 |
Diabetes (%) | 10/45 (22.2) | 2/8 (25.0) | 0.588 |
Primary disease (HCC: others) | 24: 21 | 5: 3 | 0.466 |
PTPE (%) | 2/45 (4.5) | 2/8 (25.0) | 0.104 |
History of hepatitis virus (HBV: HCV: no) | 5: 4: 36 | 1: 3: 4 | 0.090 |
Child–Pugh classification (A: B: C) | 44: 1: 0 | 8: 0: 0 | 0.849 |
Liver damage classification (A: B: C) | 39: 6: 0 | 7: 1: 0 | 0.717 |
White blood cell (/μL) | 5340 (4460–6560) | 5005 (4285–5928) | 0.533 |
Platelet (× 104/μL) | 19.6 (16.5–24.4) | 17.7 (14.7–19.7) | 0.275 |
Prothrombin activity (%) | 103 (97–115) | 97 (95–105) | 0.346 |
Aspartate transaminase (IU/L) | 25 (22–40) | 25 (20–33) | 0.617 |
Alanine transaminase (IU/L) | 22 (15–32) | 18 (15–21) | 0.371 |
Total bilirubin (mg/dL) | 0.7 (0.6–1.1) | 0.9 (0.6–1.1) | 0.874 |
Alkaline phosphatase (IU/L) | 230 (202–285) | 202 (182–259) | 0.398 |
γ-Glutamyltranspeptidase (IU/L) | 41 (23–66) | 52 (26–113) | 0.471 |
Albumin (g/dL) | 4.2 (3.9–4.4) | 4.1 (3.6–4.2) | 0.233 |
Cholinesterase (IU/L) | 278 (240–324) | 260 (221–285) | 0.486 |
Total cholesterol (mg/dL) | 190 (155–214) | 196 (177–202) | 0.583 |
C-reactive protein (mg/dL) | 0.09 (0.04–0.22) | 0.43 (0.08–0.74) | 0.128 |
HbA1c (%) | 6.0 (5.5–6.5) | 5.9 (5.5–5.9) | 0.456 |
ICG R15 (%) | 15.5 (11.3–22.5) | 16.7 (13.2–26.7) | 0.243 |
NLR | 2.96 (2.04–3.90) | 3.86 (2.89–4.41) | 0.233 |
PLR | 157.5 (116.0–254.1) | 202.9 (140.7–243.8) | 0.441 |
LMR | 3.43 (2.67–4.76) | 2.71 (2.51–3.98) | 0.512 |
CLR | 7.51 (4.02–16.39) | 24.49 (9.83–101.19) | 0.039 |
CAR | 0.023 (0.009–0.056) | 0.100 (0.019–0.213) | 0.142 |